@paradigmmedcom

paradigmmedcom has been a member of Linktree for 7 years and joined in September 2019. The social media accounts linked to from paradigmmedcom are: • Facebook • Instagram • LinkedIn • X Besides social media accounts, paradigmmedcom has populated their site with: • Visit our Website! • Paradigm Course Catalog • Partnering for Personalized Care: SDM in the Management of CL • Partnering for Personalized Care: SDM in the Management of CLL • Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making • Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia • Managing IDH & FLT3-Mutant AML: Precision in Practice • Facial Skin Quality: Define, Refine, and Renew A comprehensive approach to understanding, optimizing, and refreshing facial skin quality • Moving Beyond Misconceptions: The Reality of Sustained Delivery Therapies in Retina Practice • Incorporating Updates in Advanced Thyroid Cancers: The Role of Targeted Therapies for DTC, ATC, and MTC • Moving Beyond Injection Burden: Breakthroughs in Sustained Retinal Delivery • New and Emerging Mechanisms in the Treatment of Systemic Lupus Erythematosus • Case-by-Case: Applying New Evidence to the Treatment of Systemic Lupus Erythematosus • Optimizing First-Line Treatment of Advanced RCC in the Era of Combination Therapies • Trials Vs Reality: Matching Clinical and Real-World Evidence With Second-Generation Retinal Therapies • The Science and Art of Retina: Exploring the Role of Ang-2 and VEGF Inhibition Across Common Clinical Scenarios • Incorporating New Data Into Patient Care for Lupus Nephritis • Taking Action to Reduce Pain at IUD Insertion: Demonstration Techniques for Paracervical Block at IUD Insertion • Molluscum Contagiosum: To Treat or Not to Treat New and Emerging Treatment Strategies • The Expanding IBD Toolbox: Targeting TL1A • Innovations in Sustained Treatment of nAMD: An Update on TKI Therapies From ARVO 2026 • Treatment of RVO with Macular Edema Using New Anti-VEGF Agents | Eye Conenct • paradigmmed.org • Decision Points in CSU: Ten Questions Asked and Answered • Advancements in Idiopathic Nephrotic Syndrome: Updates on Clinical Trial Data and Management • Driving Toward Better Schizophrenia Care: Finding Another Route in a Complex Disease With Long-Acting Injectable Medications • The Latest Updates on the Role of HER2-Low and HER2-Ultralow in Treatment Selection for Metastatic Breast Cancer • Applying New Guidelines and New Treatments for Patients With Lupus Nephritis • Advances in Primary Membranous Nephropathy: A Clinical Update on Management • Discovering New Targets and Unique Strategies to Treat Sjögren’s Disease • Expert Analysis of HER2-Low and HER2-Ultralow Updates to Pathology Practice • Food Allergy: Best Practices in Shared Decision-Making • Transforming AML Care: Expert Approaches to IDH- and FLT3-Mutant Management • Expert Insights on Managing IDH- and FLT3-Mutant AML: Bringing Precision Medicine to Daily Practice • Imaging-Based Retinal Decision-Making in the Era of Second-Generation Therapy • 1415-5 Did You Know? Getting Into the Details About Managing DR/DME – Patient Simulation - DME • Accredited Activity 1416-2 - nAMD • The Many Faces of Neovascular Retinal Disease: Individualizing the Use of Sustained Delivery Therapy • Improving Outcomes for Patients With Tenosynovial Giant Cell Tumor • New Anti-VEGF Therapies For nAMD | AAO | Eye Connect • Diabetic Retinopathy: Durable Anti-VEGF Strategies for DME Treatment • Treatment of Macular Edema Secondary to RVO With Intravitreal Anti-VEGF Therapy • Beyond the Clinical Trials: The Real-World Impact of Second-Generation Therapy • Accredited Activity A1403-1 – AAO Eye Connect RVO • Accredited Activity 1416-4 - nAMD • Reading Between the Lines: Nuanced Decision-Making With Sustained Delivery Therapies • “Delivering” on the Promise of Sustained Treatment: Innovations in Long-Term Disease Control • Learn and earn 1.0 CME credit in this whiteboard webinar on Giant Cell Arteritis diagnosis, clinical trial data, and guideline-recommended treatment strategies • Infographic-Enhanced Journal Club Activity! Learn to describe the rationale for targeting HER3 in solid tumors, and summarize the latest data from ongoing clinical trials. Earn up to 0.25 CME credit • Check It Out! Learn to describe the mechanisms of action for targeted agents, as well as make appropriate treatment plans and decisions for patients with psoriasis/PsA. Earn up to 1.0 FREE CME credits! • NEW ACTIVITY! Learn to examine the role of pathways beyond VEGF-A, compare treatments for neovascular retinal diseases, and select appropriate therapies for patients with nAMD & DME. • Review concepts of MCED tests, including detection via liquid biopsy, data supporting use as a screening tool, and identifying potential MCED test candidates • NEW MDS/AML interactive infographic #CE activity! Earn up to 0.50 hour CME or 0.5 contact hour (0.05 CEU) pharmacy credits. • GOLD DIGITAL HEALTH AWARD WINNER: The Future is Now: Targeting B Cells in Lupus Nephritis • Optimizing Outcomes for Molluscum Contagiosum: Current and Emerging Treatment Strategies • Systemic Symptoms Associated With Breast Implants: Charting Patients’ Journeys With Their Primary Care Physician • BRONZE DIGITAL HEALTH AWARD WINNER: Getting to Control: Personalized Care to Address Health Inequities in the Diagnosis of Uncontrolled Severe Asthma and Treatment With Add-on Maintenance Biologic Therapy • MERIT DIGITAL HEALTH AWARD WINNER: Seeking Closure in Perianal Fistulizing Crohn’s Disease - Research Wrap-Up 1: Efficacy and Safety of Stem Cell Therapy for Complex Perianal Fistulas in Patients With Crohn’s Disease • REGISTER FOR LIVE OR VIRTUAL: "Update in Food Allergy Management" • MERIT DIGITAL HEALTH AWARD WINNER: A 22-Year-Old Presents With Shaving Bumps: A Mystery Case Presentation • Advances in Regenerative.. • [GOLD] Alzheimer's Disease Dual-Tracked Interactive DASHboard Webinar • [GOLD] How Dry Am I? A Case-Based Guide to Treating Retinal Vascular Diseases • [SILVER] The Expanding Use of Immunotherapies for Melanoma: Advances and Clinical Applications • [BRONZE] Psoriasis Prime Time: TYK Inhibition in Hard-to-Treat Psoriasis • Advances in Durable Treatments for the Management of nAMD • The Expanding Use of Immunotherapies for Melanoma: Advances and Clinical Applications • Reduce Vision Loss in nAMD Using Long-Acting Anti-VEGF Therapies • Treatment-Naïve DME - A Case Consult | Eye Connect • Revolutionizing Neovascular Retinal Disease Treatment: Update on Tyrosine Kinase Inhibitors and Gene Therapies • www.eye-connect.org • A Treatment-Naïve Patient With PDR and DME – Case Consult - DME • Guideline Adherent Care in the Management of Glaucoma - A Just in Time Sorting Game Case • Recalcitrant DME – A CME Case Consult - DME • Using Durable Next-Generation Anti-VEGF Agents to Treat DME • Conversations in Tailoring Treatment of Complex Patients With Inflammatory Bowel Disease • CrowdWisdom • Informed Choices in NSCLC: Optimal Use of Immunotherapies Across All Stages of Disease • Adapting to Durable Anti-VEGF Strategies for DME Treatment • Ask the Experts: Insights on Influenza Diagnosis and Management • In the Clinic: A Case-Based Discussion on Managing CSU • New Horizons in the Management of Chronic Spontaneous Urticaria • Diagnosis and Management of CSU Across Diverse Skin Colors: A Case Consult • New and Noteworthy Updates in DME Management | Infographic • Psoriasis Prime Time: The Role of TYK Inhibition in Psoriasis • Psoriasis With Scalp Involvement in a Patient With Skin of Color • Accredited Activity 1345-5 - nAMD • Accredited Activity 1345-4 - nAMD • Accredited Activity 1345-3 - nAMD • Accredited Activity 1345-2 - nAMD • Accredited Activity 1345-1 - nAMD